Report cover image

Europe Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Publisher The Insight Partners
Published Sep 01, 2025
Length 140 Pages
SKU # TIP20577473

Description

The European human microbiome market is projected to grow significantly, reaching approximately USD 999.66 million by 2031, up from USD 204.79 million in 2023, reflecting a compound annual growth rate (CAGR) of 21.9% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: France, Germany, the UK, and the Rest of Europe. Europe plays a crucial role in the global human microbiome market and is anticipated to experience strong growth during the period from 2023 to 2031. This growth is driven by an increase in research studies focused on the human microbiome and a rise in chronic diseases and disorders. Additionally, the expansion of various research initiatives related to human microbiomes is expected to be a primary factor propelling market growth in Europe.

Market Segmentation Analysis

The Europe human microbiome market can be analyzed through several key segments: type, application, and disease type.

By Type: The market is categorized into products and software/services. In 2023, the product segment dominated the market, which is further divided into probiotics and prebiotics.
By Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
By Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT issues leading the market in 2023.

Market Outlook

The growth and dynamics of the human microbiome industry are significantly influenced by investments from major market players. These companies are heavily investing in research and development to create innovative probiotics, diagnostics, and microbiome-based treatments. Such investments foster innovation, leading to the discovery of new strains, mechanisms of action, and therapeutic applications. Clinical trials, which require substantial funding, are essential for validating the safety and efficacy of microbiome-related products.

For instance, Kanvas Biosciences, a leader in microbiome mapping technology, secured USD 12 million in a Pre-Series A funding round in June 2023. This funding will support the advancement of their proprietary platform technology aimed at revolutionizing drug development for microbiome-related diseases. Furthermore, collaborations among companies enhance resource sharing, expertise, and technological advancements, accelerating product development. A notable partnership was formed in July 2023 between Nestlé, the largest food and beverage company globally, and APC Microbiome Ireland, a leading research center, focusing on various aspects of the human microbiome to develop new health-enhancing products. Currently, around 120 companies are investing in microbiome analysis, with numerous startups entering the sector. Key investors include Flagship Pioneering, Seventure Partners, and BioGaia, indicating that increased investment from these players is likely to drive market growth.

Country Insights

The European human microbiome market includes countries such as the UK, Germany, France, Italy, Spain, and others. Germany emerged as the largest market in 2023, recognized as a significant hub for biotechnological research in Europe and globally. This is attributed to the presence of major biotechnology firms, advanced research facilities, and substantial funding for research and development. The ongoing R&D activities and favorable government regulations for microbiome therapeutics development in Germany present lucrative opportunities. For example, in 2022, Vagisan ProbioFlora, produced by Dr. Wolff Group, was reclassified and received medicinal product status, positively impacting the broader microbiome-driven pharmaceutical industry.

In March 2023, mbiomics GmbH announced a successful first closing of its Series A financing round, raising EUR 13 million (approximately USD 15 million), led by MIG Capital with participation from High-Tech Gründerfonds, Bayern Kapital, and private investors. Mbiomics utilizes its proprietary high-resolution profiling platform to design effective microbial consortia for precision therapies and improve patient selection and monitoring in clinical trials.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe human microbiome market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe human microbiome market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

Table of Contents

140 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Europe Human Microbiome Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Europe Human Microbiome Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Significant Investments by Key Market Players
5.1.2 Government Initiatives
5.2 Market Restraints
5.2.1 Challenges During Production of Microbiome
5.3 Market Opportunities
5.3.1 Robust Investment in Research and Development
5.4 Future Trends
5.4.1 Emergence of Precision Medicine
5.5 Impact of Drivers and Restraints:
6. Human Microbiome Market – Europe Analysis
6.1 Europe Human Microbiome Market Revenue (US$ Million), 2021–2031
6.2 Europe Human Microbiome Market Forecast Analysis
7. Europe Human Microbiome Market Analysis – by Type
7.1 Product
7.1.1 Overview
7.1.2 Product: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.2 Software and Services
7.2.1 Overview
7.2.2 Software and Services: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8. Europe Human Microbiome Market Analysis – by Application
8.1 Therapeutics
8.1.1 Overview
8.1.2 Therapeutics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.2 Diagnostics
8.2.1 Overview
8.2.2 Diagnostics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.3 Research
8.3.1 Overview
8.3.2 Research: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9. Europe Human Microbiome Market Analysis – by Disease Type
9.1 Obesity
9.1.1 Overview
9.1.2 Obesity: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.2 Diabetes
9.2.1 Overview
9.2.2 Diabetes: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3 Autoimmune Disorder
9.3.1 Overview
9.3.2 Autoimmune Disorder: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.4 Cancer
9.4.1 Overview
9.4.2 Cancer: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.5 GIT
9.5.1 Overview
9.5.2 GIT: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10. Europe Human Microbiome Market – Country Analysis
10.1 Europe
10.1.1 Europe Human Microbiome Market – Revenue and Forecast Analysis – by Country
10.1.1.1 Europe Human Microbiome Market – Revenue and Forecast Analysis – by Country
10.1.1.2 United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.2.1 United Kingdom: Europe Human Microbiome Market Share – by Type
10.1.1.2.2 United Kingdom: Europe Human Microbiome Market Share – by Product
10.1.1.2.3 United Kingdom: Europe Human Microbiome Market Share – by Application
10.1.1.2.4 United Kingdom: Europe Human Microbiome Market Share – by Disease Type
10.1.1.3 Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.3.1 Germany: Europe Human Microbiome Market Share – by Type
10.1.1.3.2 Germany: Europe Human Microbiome Market Share – by Product
10.1.1.3.3 Germany: Europe Human Microbiome Market Share – by Application
10.1.1.3.4 Germany: Europe Human Microbiome Market Share – by Disease Type
10.1.1.4 France: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.4.1 France: Europe Human Microbiome Market Share – by Type
10.1.1.4.2 France: Europe Human Microbiome Market Share – by Product
10.1.1.4.3 France: Europe Human Microbiome Market Share – by Application
10.1.1.4.4 France: Europe Human Microbiome Market Share – by Disease Type
10.1.1.5 Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.5.1 Italy: Europe Human Microbiome Market Share – by Type
10.1.1.5.2 Italy: Europe Human Microbiome Market Share – by Product
10.1.1.5.3 Italy: Europe Human Microbiome Market Share – by Application
10.1.1.5.4 Italy: Europe Human Microbiome Market Share – by Disease Type
10.1.1.6 Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.6.1 Spain: Europe Human Microbiome Market Share – by Type
10.1.1.6.2 Spain: Europe Human Microbiome Market Share – by Product
10.1.1.6.3 Spain: Europe Human Microbiome Market Share – by Application
10.1.1.6.4 Spain: Europe Human Microbiome Market Share – by Disease Type
10.1.1.7 Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.1.1.7.1 Rest of Europe: Europe Human Microbiome Market Share – by Type
10.1.1.7.2 Rest of Europe: Europe Human Microbiome Market Share – by Product
10.1.1.7.3 Rest of Europe: Europe Human Microbiome Market Share – by Application
10.1.1.7.4 Rest of Europe: Europe Human Microbiome Market Share – by Disease Type
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Human Microbiome Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 MaaT Pharma
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Ferring Holdings SA
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 AOBiome Therapeutics Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Finch Therapeutics Group Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Financial Overview
12.4.4 SWOT Analysis
12.4.5 Key Developments
12.5 Seres Therapeutics Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Merck & Co Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Yakult Honsha Co., Ltd.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Rebiotix, Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 IFF Nutrition & Biosciences
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Synthetic Biologics, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 List of Abbreviations
List of Tables
Table 1. Europe Human Microbiome Market Segmentation
Table 2. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Table 3. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Type
Table 4. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Application
Table 5. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Disease Type
Table 6. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 7. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 8. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 9. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 10. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 11. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 12. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 13. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 14. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 15. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 16. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 17. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 18. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 19. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 20. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 21. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 22. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 23. ADULT OBESITY, 2030
Table 24. CHILD OBESITY, 2030
Table 25. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 26. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 27. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 28. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 29. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 30. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 31. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 32. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 33. Recent Organic Growth Strategies in the Human Microbiome Market
Table 34. Recent Inorganic Growth Strategies in the Human Microbiome Market
Table 35. List of Abbreviations
List of Figures
Figure 1. Europe Human Microbiome Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Europe Human Microbiome Market – Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Europe Human Microbiome Market Revenue (US$ Million), 2021–2031
Figure 6. Europe Human Microbiome Market Share (%) – by Type (2023 and 2031)
Figure 7. Product: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 8. Software and Services: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 9. Europe Human Microbiome Market Share (%) – by Application (2023 and 2031)
Figure 10. Therapeutics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 11. Diagnostics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 12. Research: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 13. Europe Human Microbiome Market Share (%) – by Disease Type (2023 and 2031)
Figure 14. Obesity: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 15. Diabetes: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 16. Autoimmune Disorder: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 17. Cancer: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 18. GIT: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 19. Others: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 20. Europe Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 21. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 22. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 23. France: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 24. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 25. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 26. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 27. Growth Strategies in the Human Microbiome Market

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us